BNC Korea Co Ltd
KOSDAQ:256840
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BNC Korea Co Ltd
Cash Equivalents
BNC Korea Co Ltd
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BNC Korea Co Ltd
KOSDAQ:256840
|
Cash Equivalents
₩96.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Cash Equivalents
-₩300
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Cash Equivalents
₩10.2B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash Equivalents
₩66.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
25%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Cash Equivalents
₩112B
|
CAGR 3-Years
65%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
BNC Korea Co Ltd
Glance View
BNC Korea Co., Ltd. researches and develops strategic application products which include medical devices, pharmaceuticals, and cosmetic products containing physiologically active substances by processing hyaluronic acid and collagen. The company is headquartered in Daegu, Daegu. The company went IPO on 2016-12-28. The firm's main products include hyaluronic acid (HA) fillers, collagen wound dressings, antiadhesion materials and collagen tissue supplements, and others. In addition, the Company produces and sells cosmetics, medicines and medical devices, among others.
See Also
What is BNC Korea Co Ltd's Cash Equivalents?
Cash Equivalents
96.5B
KRW
Based on the financial report for Sep 30, 2025, BNC Korea Co Ltd's Cash Equivalents amounts to 96.5B KRW.
What is BNC Korea Co Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
65%
Over the last year, the Cash Equivalents growth was 18%. The average annual Cash Equivalents growth rates for BNC Korea Co Ltd have been -7% over the past three years , 65% over the past five years .
